Highlights

  • Firebrick received approval for Nasodine Nasal Spray in Indonesia during FY26.
  • US online sales of Nasodine Nasal Spray increased 82% during FY26.
  • The company launched Nasodine Throat Spray in Singapore and Fiji.
  • Firebrick received a $293,000 R&D Tax Incentive payment for FY26 expenditure.

Firebrick Pharma Limited (ASX:FRE) is a healthcare company focused on developing and commercialising novel formulations and uses of povidone-iodine (PVP-I). Its lead product, Nasodine® Nasal Spray, is being introduced across international markets, supported by a broader Nasodine product portfolio. During FY26, Firebrick progressed from Research and Development activities towards commercialisation through market approvals, product launches and expansion initiatives.

Nasodine Commercialisation Progresses Across International Markets

Firebrick Pharma continued advancing the commercialisation of Nasodine products during FY26, with market launches, regulatory progress and increased sales activity across selected regions.

The company’s first product, Nasodine Nasal Spray, containing 0.5% povidone-iodine, was introduced into the United States, Singapore and Fiji. During FY26, Indonesia approved Nasodine Nasal Spray for importation and distribution, while the company continued pursuing approval in the Philippines and other markets.

Firebrick reported US online sales growth during FY26, with unit sales increasing 119% and sales Revenue increasing 82%. The company expanded its US online platform through its direct E-commerce website and an online pharmacy partner.

In Southeast Asia, Singapore continued serving as a pilot market for the Nasodine range. Firebrick identified Indonesia and the Philippines as key markets due to their larger populations and potential commercial scale.

The company also announced plans to expand Nasodine products into up to 10 markets over three years, subject to regulatory approvals and market access arrangements.

Nasodine Throat Spray and Product Pipeline Expansion

During FY26, Firebrick expanded its product portfolio with the launch of Nasodine Throat Spray, the first follow-on product under the Nasodine brand.

Nasodine Throat Spray is designed for protection from and treatment of sore throats and offers an alternative format to povidone-iodine gargles. The product was launched in Singapore and Fiji during FY26.

In Singapore, the company’s licensing partner focused initial promotion through hospitals and healthcare professionals. Firebrick reported that early Demand from the healthcare professional channel exceeded expectations, resulting in initial launch Supply being purchased and requiring additional production.

The company plans further expansion of the Nasodine portfolio, with additional products expected to be announced during FY27.

Firebrick received a $293,000 R&D Tax Incentive payment in September 2026 related to eligible FY26 R&D expenditure. The payment related to $673,000 in reported R&D costs associated with development of new products within the Nasodine range.

The company continues investing in product development while building commercial capabilities across new markets.

Financial Position and Commercialisation Strategy

Firebrick reported revenue of $106,000 for FY26, compared with $293,000 in FY25. The company recorded a net loss after tax of $3.06 million, compared with a loss of $2.63 million in the prior year.

Operating expenses remained controlled, with annual expenses of approximately $3.08 million. The company reported operating cash burn of $2.60 million for FY26.

At 30 June 2026, Firebrick held cash and cash equivalents of $1.32 million. During FY26, the company completed share placements raising approximately $3.17 million before transaction costs.

Firebrick continues transitioning from an R&D-focused biotechnology company towards commercialisation. Key priorities include expanding Nasodine availability, developing additional products, securing distribution partnerships and progressing regulatory approvals.

The company’s future commercial progress remains linked to market access, regulatory approvals, distribution capability and additional funding requirements to support operations.

Key Insights

Firebrick Pharma’s FY26 progress centred on advancing Nasodine commercialisation, expanding international market access and developing additional products under the Nasodine brand. The company is focused on converting regulatory milestones and product development activities into broader commercial opportunities.